Guard Therapeutics is a Swedish biotech company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. The company’s investigational drug RMC-035 is being developed as a kidney protective treatment in connection with open heart surgery and kidney transplantation. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm.

A global phase 2 study, AKITA, was initiated in 2022. Learn more about the clinical development of RMC-035.

Read more

CLINICAL STUDIES

RMC-035, our lead investigational drug, is designed to mimic the body's own defense system against oxidative stress by protecting, cleaning and repairing exposed cells and tissue.

Read more

RMC-035

Acute kidney injury is a large market. 13 million people gloabally are affected every year.

Read more

INVESTOR RELATIONS

Press releases
  • 23 Sep 2022

    Presentations from Guard Therapeutics' Capital Markets Day are now available on the company's website

    Read more
  • 05 Sep 2022

    First kidney transplant recipient dosed with Guard Therapeutics' investigational drug RMC-035

    Read more
  • 19 Aug 2022

    Guard Therapeutics hosts capital markets day

    Read more
  • 01 Jun 2022  ·  Regulatory information

    Guard Therapeutics receives approval from the Swedish Medical Products Agency to conduct a clinical study of RMC-035 in kidney transplantation

    Read more
Show more
Calendar & reports
  • 16 Nov 2022

    Interim report July-September 2022

    Read more
  • 22 Feb 2023

    Year-end report 2022

    Read more
Reports, presentations & in media
  • 21 Sep 2022 / Presentation

    Guard Therapeutics Capital Markets Day

    Read more
  • 13 Sep 2022 / Presentation

    ABGSC -Investor Day Seminar

    Read more
  • 18 May 2022 / Presentation

    ABGSC Life Science Summit (Stockholm, Sweden)

    Read more
  • 27 Apr 2022 / Presentation

    Life Science Investor Conference 27 April 2022 (Copenhagen, Dennmark)

    Read more
Show more